Product Information
TETRACYCLINE 250 MG CAPSULE is a generic product labeled by Actavis Pharma, Inc., priced at $0.2472 per EA under NDC 00591247401. Its NADAC has been published 539 times since Jun 8, 2016.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00591247401
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TETRACYCLINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA061837FDA Approved
Before 1982
TE Code
AB
On Market Since
8/15/2011
Pharmacological Classes
Price Statistics
The NADAC for TETRACYCLINE 250 MG CAPSULE has been published 539 times since Jun 8, 2016, and over the history we have for it it has declined 95.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2472 per EA |
|---|---|
| All-time high | $5.7359 (Apr 12, 2017) |
| All-time low | $0.2462 (Aug 19, 2026) |
| 52-week high | $0.7024 |
| 52-week low | $0.2462 |
| Median price | $1.0134 |
| Average price | $1.8107 |
| Largest weekly change | +72.0% (Sep 22, 2021) |
| Weeks tracked | 539 |
| Tracking since | Jun 8, 2016 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tetracycline Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tetracycline-class Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TETRACYCLINE 250 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for TETRACYCLINE 250 MG CAPSULE, manufactured by Actavis Pharma, Inc., is $0.2472 per EA (NDC 00591247401), effective Sep 30, 2026.
How has the price of TETRACYCLINE 250 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for TETRACYCLINE 250 MG CAPSULE has declined 95.3%. It has been tracked across 539 weekly CMS publications since Jun 8, 2016.
What are the highest and lowest recorded NADAC prices for TETRACYCLINE 250 MG CAPSULE?
Since Jun 8, 2016, the NADAC for TETRACYCLINE 250 MG CAPSULE has ranged from a low of $0.2462 (Aug 19, 2026) to a high of $5.7359 (Apr 12, 2017), with a median of $1.0134 per EA.
Are there cheaper alternatives to TETRACYCLINE 250 MG CAPSULE?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TETRACYCLINE 250 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures TETRACYCLINE 250 MG CAPSULE?
TETRACYCLINE 250 MG CAPSULE (NDC 00591247401) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.